Nantilus
Neurosarcoïdose : caractéristiques cliniques et paracliniques des atteintes du système nerveux central
Neurological localizations of central nervous system are heterogenous and rare. Our main objective is to describe the clinical, biological and MRI pattern of this population. We retrospectively included 118 patients : 38 with isolated neurosarcoidosis (NS), 80 with NS associated with systemic sarcoi...
Enregistré dans:
| Auteurs principaux : | , , |
|---|---|
| Collectivités auteurs : | , |
| Format : | Thèse ou mémoire |
| Langue : | français |
| Titre complet : | Neurosarcoïdose : caractéristiques cliniques et paracliniques des atteintes du système nerveux central / Amélie Dos Santos; sous la direction de Sandrine Wiertlewski |
| Publié : |
2020 |
| Description matérielle : | 1 vol. (70 f.) |
| Note de thèse : | Thèse d'exercice : Médecine. Neurologie : Nantes : 2020 |
| Sujets : | |
| Documents associés : | Reproduit comme:
Neurosarcoïdose |
| Résumé : | Neurological localizations of central nervous system are heterogenous and rare. Our main objective is to describe the clinical, biological and MRI pattern of this population. We retrospectively included 118 patients : 38 with isolated neurosarcoidosis (NS), 80 with NS associated with systemic sarcoidosis. The NS is the initial presentation in 77,9% of patients, with cranial nerves involvement (36,4%), medullary symptoms (22,8%) and seizures (21,2%). Patients were knowed to have systemic sarcoidosis in 20,6%. The diagnosis was concomittant of NS in 48,2% and post-NS in 52,8%. The ECA are increased in only 20,7%. The meningitis are present in 44,6% and hyperproteinorachia are frequent (69,5%). MRI results showed white matters abnormalities. The most useful treatment of NS is corticosteroids. Immunosupressive drugs are used in steroids resistant patients and to limit side-effects. Methotrexate and cyclophosphamid are frequently used with a good efficacy. Some study will be necessary to confirm efficacy and safety of anti-TNFa. |
|---|---|
| Variantes de titre : | Neurosarcoidosis : clinical, biological and MRI presentation of central nervous system disease |
| Notes : | Autre(s) contribution(s) : David Laplaud (Président du jury) |
| Bibliographie : | Bibliogr. f. 64-69, 84 réf. |